ArticleJournal of natural medicines2026
Rice-derived glucosylceramides activate innate immune responses in myeloid lineage differentiated dendritic cells via toll-like receptors 2 and 4.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Rice-derived glucosylceramides (GlcCer) consist of multiple molecules that comprise different types of sphingoid bases and saturated fatty acids. These GlcCer are critical for epidermal barrier function and exert anti-melanogenic effects. Regarding their effects on the immune system, a dead cell-derived GlcCer [d18:2/24:1] was shown to enhance the activation of antigen-presenting cells via Mincle receptors. However, the immunomodulatory effects of rice-derived GlcCer have yet to be examined. Therefore, we herein investigated the effects of rice-derived GlcCer on dendritic cell (DC) activation. Among rice-derived GlcCer, GlcCer[d18:2(4E,8Z)/18:0] (10 μM) significantly enhanced IL-6 production by iMylc DC established from induced pluripotent stem cells. CD40 and CD80 expression was significantly upregulated by GlcCer[d18:2(4E,8Z)/18:0] in aMylc DC derived from human peripheral blood mononuclear cells. In a toll-like receptor (TLR) competitive binding assay using TLR antagonists, GlcCer[d18:2(4E,8Z)/18:0] bound to TLR2 and 4. The antigen-presenting abilities of GlcCer[d18:2(4E,8Z)/18:0] and GlcCer[d18:2(4E,8Z)/26:0] were confirmed by the mixed lymphocyte reaction test, which showed a significant T-cell proliferative effect. These results indicate that GlcCer[d18:2(4E,8Z)/18:0] activated DC being sensed by TLR2 and 4 and induced T-cell responses through the expression of CD40 and CD80. Therefore, the limited GlcCer molecules in rice appear to promote innate immune responses on DC.
Indexed as
Identifiers
41136819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.